News | Neuro Imaging | June 12, 2018

Volumetric Software Helps Determine Non-Alzheimer's Causes of Memory Loss

UCLA study uses Neuroreader software to measure brain shrinkage patterns on MRI scans

Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

Hippocampal volume increase in depressed patient on MRI

Hippocampal volume increase from baseline in a depressed patient who underwent a brain health intervention program at UCLA involving increased physical activity and cognitive training. Over the course of one year, hippocampal volume increased by 4.6 percent at the second time point with decreased irritability following depression treatment. The patient had an amyloid positive PET scan and experienced cognitive decline over the following 2 years with concurrent decreased hippocampal volume. Neuropsychological testing was at the first percentile for memory by 2017. Image courtesy of Somayeh Meysami, M.D., Cyrus A. Raji, M.D., Ph.D., Verna R. Porter, M.D., et al.

 UCLA Brain MRI poster memory loss

June 12, 2018 — According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when memory loss is caused by treatable issues other than Alzheimer’s Disease. The study was presented at the 2018 American Academy of Neurology Conference, April 21-27 in Los Angeles.

Alzheimer’s is the most common cause of memory problems in the elderly, but there are several treatable problems with similar symptoms, including vascular diseases such as hypertension, alcohol use and psychiatric disorders.

The new technology was the U.S. Food and Drug Administration (FDA)-cleared Neuroreader volumetric software. The software was applied to traditional magnetic resonance imaging (MRI) scans to analyze 22 patients, and found that only five showed brain shrinkage patterns characteristic of Alzheimer’s. The majority of the remaining cases were a combination of other causes, such as bipolar disorder and vascular disease.

For more information: www.brainreader.net

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
TeraRecon Unveils iNtuition AI Data Extractor
News | Advanced Visualization | July 03, 2019
Artificial Intelligence (AI) and advanced visualization company TeraRecon announced its new iNtuition AI Data Extractor...
A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model.

A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model. Photo courtesy of Nicole Wake, Ph.D.

Feature | Advanced Visualization | July 02, 2019 | By Jeff Zagoudis
Three-dimensional (3-D) printing and...